New data to be presented at the 2025 AES Annual Meeting indicate sustained reductions in seizure frequency as early as two weeks after treatment initiation with bexicaserin1 Bexicaserin is an investigational compound in development for […]
Tag: H. Lundbeck A/S
Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
New data to be presented at the 2025 AES Annual Meeting indicate sustained reductions in seizure frequency as early as two weeks after treatment initiation with bexicaserin1 Bexicaserin is an investigational compound in development for […]
